Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Donate

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Donate

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Donate

News

Opportunities for overcoming tuberculosis, New treatment regimens

September 1, 2005

For centuries, tuberculosis (TB) has targeted the most vulnerable populations during their most productive working years, threatening economic and social […]

News

Investing in Health R&D for the Millennium Development Goals

July 30, 2005

The UN Millennium Project commissioned and published a series of action plans to outline the steps necessary to achieving the

News

G8 Recognizes Non-Profit R&D Model for Neglected Diseases

July 11, 2005

As part of its historic $50 billion package for Africa, the G8 nations this year announced their support for the

News

TB Alliance Appoints Nina Schwalbe as Director of Policy

July 5, 2005

NEW YORK CITY (July 5, 2005) — The TB Alliance announced the appointment of Ms. Nina Schwalbe as Director of

News

Drug Companies Appeal For G8 Backing to Fight Diseases

June 17, 2005

Financial Times Published: June 17 2005 DRUG COMPANIES APPEAL FOR G8 BACKING TO FIGHT DISEASES Some of the world’s leading

News

TB drug trials begin in Nebraska

June 16, 2005

News

Nonprofit to test novel tuberculosis drug worldwide

June 14, 2005

SAN FRANCISCO – Volunteers in Nebraska have begun receiving an experimental tuberculosis drug that developers hope will soon turn the

News

First Tuberculosis Drug Developed by a Non-profit Begins Clinical Trials

June 14, 2005

Trial is First in TB Alliance’s Growing Pipeline of Drugs — Provides Model for Future Drug Development NEW YORK CITY

News

TB Drug Research Picks Up the Pace

June 8, 2005

News

TB Alliance Expands Discovery Projects with GlaxoSmithKline

May 12, 2005

The TB Alliance and GlaxoSmithKline (GSK) announced that they would jointly pursue a broad drug discovery program to improve the

← Previous 1 … 41 42 43 … 65 Next →

About
Why New TB Drugs
R&D
Access
News

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328

Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list

Email Address

Treat 2,037,998 People

In the first fifteen years following BPaL’s approval, more than 2 million people treated for drug-resistant TB will be treated with BPaL/M. This means millions of people will benefit from improved treatment outcomes and experiences.

Restore 5,120,433 healthy life years

When TB doesn’t kill, it often leaves people with long periods of disability. By curing drug-resistant TB faster and more effectively, BPaL/M helps people not only survive, but recover faster, and avoid long term disabilities. That means fewer years lost to illness and more people living fully again, faster. In its first 15 years of approval, BPaL/M will result in people experiencing more than 5 million more healthy years of life.

Save an Additional 191,222 lives

BPaL/M has higher treatment success rates than previous therapies and use of these regimens is rapidly scaling up globally. In its first 15 years of approval, BPaL/M will save an additional 190,000 lives by replacing older treatments with lower success rates.

Save the world $1.29B USD

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people receiving treatment.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.

179,697 more people will complete treatment

Traditionally, many people receiving treatment for drug-resistant TB did not complete therapy. This was often due to the length and side effects of treatments. Those who don’t complete treatment may remain contagious and infect others, as well as suffer increased disability or death. In its first 15 years of approval, BPaL/M will lead to nearly 180,000 additional people completing treatment.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” In its first 15 years of approval, BPaL/M will lead to more than 330,000 additional people with drug-resistant TB being successfully treated.